NCT06711770Not yet recruiting
Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)
Characterization of the Effect of G-CSF on the Interactions Between MDSC and Cancer Stem-cells in Non-small Cell Lung Cancers (CIRCUIT)
Source: ClinicalTrials.gov · Last updated 30 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to immunologic (myeloid immunosuppressive cells) and non-immunologic (cancer stem- cells (CSC)) mechanisms. CSC are able to circulate within blood, protected from destruction by immunosuppressive cells such as MDSC. Some factors such as G-CSF, administered to lower febrile neutropenia, should modulate properties of MDSC and CSC, but data are contradictory, and literature remain poor regarding its effects on the interactions between MDSC and CSC in blood clusters. Indeed, this project aims at better characterizing the effect of G-CSF on these interactions and on their functions in NSCLC patients receiving G-CSF.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 9 Oct 2024
- Start date
- Dec 2025
- Primary completion date
- Dec 2028
- Lead sponsor
- University Hospital, Bordeaux
- Diseases
- Lung cancer
- NCT number
- NCT06711770
What you commit to
- Study type: Interventional
- Planned participants: 30
- From Dec 2025 to the primary completion date, Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Corticosteroids \> 10 mg/j
- Concomitant cancer
- Patient within the exclusion period for another clinical trial, or participating to another interventional trial within 30 days before the beginning of this project
Other illness
- Non-metastatic disease
- Autoimmune disease
- Active and uncontrolled HIV infection
- Psychiatric or medical conditions that prohibit the understanding and rendering of informed consent
- Patient with a deprived liberty condition
Lab values
- Actionable mutation or genomic alteration in EGFR, ALK or ROS1
Other
- Patient with a small cell lung carcinoma
- Pregnancy or lactating women
- Patient under a legal protection measure
- Patient incapable of giving signed informed consent
Who the study is looking for
- Patients (male or female) aged ≥ 18 years
- Histological or cytological proven lung adenocarcinoma, metastatic or locally advanced not accessible to local therapy
- Receiving chemotherapy and immunotherapy as first-line treatment
- Signed written informed consent (no later than the day of inclusion, and before the blood sample collection)
- Patient affiliated or beneficiary to a health security system;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Bordeaux, service d'Oncologie Médicale Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.